Immunotherapy
New Study Reveals How Cancer Reprograms Immune Cells, Offering Hope for Immunotherapy Breakthrough
A study uncovering how cancer cells reprogram immune cells to support tumor growth could improve immunotherapy response rates, which currently fail in 80% of patients.
GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Industry Shift to In Vivo Cancer Therapies
GeoVax highlights its gene-directed enzyme prodrug therapy Gedeptin as a potential immune-sensitizing platform that could enhance checkpoint inhibitor efficacy in solid tumors, aligning with rising industry investment in simplified in vivo cancer treatments.
MIT and Harvard Researchers Develop Enhanced Natural Killer Cell Therapy for Cancer Treatment
Researchers from MIT and Harvard Medical School have engineered modified natural killer cells that show promising results in fighting cancer while avoiding immune system rejection, potentially transforming cancer immunotherapy approaches.
GeoVax to Report Q3 2025 Financial Results and Provide Business Update
GeoVax Labs will report its third quarter 2025 financial results and provide updates on its clinical-stage vaccine and immunotherapy programs, including COVID-19 vaccines for immunocompromised patients and oncology treatments.
Lifordi Immunotherapeutics Advances Glucocorticoid ADC LFD-200 into Phase 1 Rheumatoid Arthritis Trial Following Promising Nonclinical Data
Lifordi Immunotherapeutics has initiated Phase 1 clinical trials for LFD-200, a novel antibody-drug conjugate that delivers glucocorticoids directly to immune cells, potentially overcoming the systemic toxicity limitations that have restricted steroid use in autoimmune diseases for decades.
New Research Identifies Key Mechanism Behind Cancer Immunotherapy Failures
Ohio State University researchers have discovered a previously unknown stress pathway that explains why immunotherapy fails in most cancer patients, potentially paving the way for more effective treatments.
Lund University Researchers Identify Mechanism Allowing Leukemia Cells to Evade Immune System
Researchers at Lund University have discovered why acute myeloid leukemia cells resist immunotherapy, potentially paving the way for more effective treatments for this aggressive blood cancer.
Study Reveals Common Nutrient May Enhance Cancer-Fighting Immune Cells
University of Chicago research indicates zeaxanthin, a nutrient found in common vegetables, could boost immune system effectiveness against cancer while complementary therapies like oncolytic viruses advance.
Creative Biolabs Accelerates CAR-T Therapy Innovation with Advanced Development Platform
Creative Biolabs is enhancing CAR-T therapy research through its comprehensive development platform, offering specialized viral vectors and ready-made plasmids that address critical challenges in scalability, cost, and technical efficiency for both blood cancers and emerging solid tumor applications.
Study Links Sucralose Consumption to Reduced Effectiveness of Cancer Immunotherapy
University of Pittsburgh research reveals that regular consumption of the artificial sweetener sucralose may diminish the effectiveness of immunotherapy treatments and reduce survival times in cancer patients.
OS Therapies Advances Toward 2026 Osteosarcoma Drug Launch with FDA RMAT Designation
OS Therapies Inc. achieves critical regulatory milestones for its OST-HER2 immunotherapy, positioning for potential accelerated approval and U.S. commercial launch in 2026 to address a 40-year treatment gap in osteosarcoma.
Oncotelic Therapeutics Highlights CEO's Track Record and Clinical Pipeline Advancements
Oncotelic Therapeutics showcases CEO Dr. Vuong Trieu's substantial patent portfolio and successful drug development history while updating progress on its oncology and immunotherapy pipeline.
Oncotelic Therapeutics Advances Cancer Pipeline with Phase 3 Candidate and AI Integration
Oncotelic Therapeutics is progressing its RNA-based immunotherapy OT-101 through Phase 3 trials for pancreatic cancer while leveraging strategic partnerships and proprietary AI technology to accelerate drug development across multiple underserved disease areas.
GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference
GeoVax Labs will showcase progress on its Mpox/smallpox, COVID-19, and cancer immunotherapy programs at the upcoming H.C. Wainwright conference, highlighting advancements in vaccine development and manufacturing capabilities.
Oncotelic Therapeutics Highlights Robust Oncology Pipeline and CEO's Patent Portfolio
Oncotelic Therapeutics showcases its clinical-stage oncology and immunotherapy pipeline, including multiple late-stage candidates and rare disease programs, while emphasizing CEO Dr. Vuong Trieu's extensive intellectual property contributions that underpin the company's competitive strategy.
Nerve Damage Identified as Unexpected Cause of Cancer Immunotherapy Resistance
A multinational research team has discovered that cancer-induced nerve damage contributes to immunotherapy resistance, potentially opening new treatment avenues for patients.
New Genetic Discovery Enhances Cancer Immunotherapy Potential
A groundbreaking genetic discovery could significantly improve the effectiveness of cancer immunotherapy, offering new hope for patients with certain types of cancer.
Study Reveals Autoantibodies' Role in Enhancing Cancer Immunotherapy Efficacy
A recent study highlights the potential of autoantibodies in predicting the effectiveness of cancer immunotherapy, offering a new avenue for personalized treatment strategies.
GeoVax Advances in Vaccine Development and Immunotherapy with Promising Clinical Data
GeoVax Labs reports significant progress in its vaccine and immunotherapy pipeline, including favorable regulatory guidance for GEO-MVA and robust immune responses from GEO-CM04S1 in CLL patients, highlighting the company's potential to address urgent medical needs.
Creative Biolabs Advances Precision Immunotherapy with Fc Engineering Technology
Creative Biolabs' innovative Fc engineering technology enhances the therapeutic performance of biologics by optimizing immune effector functions, offering new avenues for treating cancers and autoimmune diseases.
Experimental mRNA Vaccine Shows Promise in Enhancing Cancer Immunotherapy
Researchers have discovered that an experimental mRNA vaccine could significantly improve the effectiveness of immunotherapy in fighting tumors, marking a potential advancement towards universal cancer vaccines.
UC Davis Study Uncovers Genetic Mutation Affecting Immunotherapy Response in Solid Tumors
A study by UC Davis scientists reveals a genetic mutation that may explain why solid tumors are unresponsive to immunotherapy, potentially leading to more effective cancer treatments.
Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance
Soligenix Inc. is developing SGX943, a novel immunotherapy that enhances the body's immune response to combat bacterial infections, addressing the critical challenge of antibiotic resistance.
Calidi Biotherapeutics Inc. Advances Oncology Pipeline and Strategic Goals in 2025
Calidi Biotherapeutics Inc. outlines significant progress in its oncology immunotherapy pipeline and strategic initiatives aimed at enhancing shareholder value and advancing cancer treatment options.
Fermented Wheat Germ Could Enhance Immunotherapy Outcomes for Cancer Patients
A clinical trial at UC Davis is exploring the potential of fermented wheat germ to improve immunotherapy results for cancer patients, offering hope for better survival rates and quality of life.
Electric Fields Found to Enhance Immune Response Against Glioblastoma
A recent study by the University of Southern California reveals that electric fields can significantly boost the immune system's fight against glioblastoma, offering hope for extended patient survival and new treatment avenues.
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. presents groundbreaking data on its lead candidate CLD-401 at the ASCO Annual Meeting, showcasing advancements in systemic oncolytic targeted immunotherapies with potential implications for cancer treatment.
Korean Researchers Develop AI Model to Enhance Cancer Immunotherapy Precision
A South Korean research team has created an innovative AI model capable of predicting patient responses to immunotherapy for colorectal and gastric cancers, potentially revolutionizing personalized cancer treatment strategies.
University of Houston Receives $3M Grant to Advance Cancer Immunotherapy Research
The Texas Cancer Prevention & Research Institute awarded the University of Houston $3 million to establish a biomarker core, potentially transforming cancer research and patient outcomes through advanced immunotherapy techniques.